American Society of Hematology (ASH)

The American Society of Hematology (ASH) is a professional organization representing hematologists. It was founded in 1958. Its annual meeting is held in December of every year and has attracted more than 30,000 attendees. The society publishes the medical journal Blood, the most cited peer-reviewed publication in the field, which is available weekly in print and online, as well as the newly launched, online, peer-reviewed open-access journal, Blood Advances.
Preliminary results from the phase 1b/2 CARTITUDE-1 study reveal early, deep, and durable responses and a safety profile consistent with prior studies with a single low-dose infusion of ciltacabtagene autoleucel in heavily pretreated patients with RRMM. Read More ›

Two-year fixed-duration treatment with venetoclax-rituximab demonstrates durable response, with a substantial proportion of patients retaining undetectable minimal residual disease 36 months after treatment cessation. Read More ›

In the FORTE trial, patients with NDMM who were transplant-eligible experienced significantly improved progression-free survival with carfilzomib + lenalidomide + dexamethasone (KRd) induction-ASCT-KRd consolidation versus either 12 KRd cycles or carfilzomib + cyclophosphamide + dexamethasone (KCd) induction-ASCT-KCd consolidation. Read More ›

The ICARIA-MM investigators studied the effects of isatuximab + pomalidomide and dexamethasone in the subgroup of frail patients with RRMM, and results support use of the regimen among these patients. Read More ›

Interim results from a phase 2 trial exploring the response to ixazomib, lenalidomide, and dexamethasone induction followed by a single autologous stem-cell transplantation, IRd consolidation, and risk-based maintenance showed an overall response rate of 93%. Read More ›

Preliminary results from this phase 1b/2 study of cobimetinib alone or plus venetoclax, with or without atezolizumab, in patients with RRMM show manageable toxicity, moderate efficacy overall, and higher efficacy for t(11;14) patients. Read More ›

Preliminary results from the GO39775 study show promising efficacy and manageable toxicity for BFCR4350A as monotherapy in patients with RRMM with high-risk cytogenetics, triple-class refractory disease, and/or prior exposure to anti-CD38 monoclonal antibodies, CAR T-cells, or antibody–drug conjugates. Read More ›

The interim results from a phase 2 trial examining the response to ixazomib, lenalidomide, and dexamethasone induction in newly diagnosed, transplant-eligible patients showed an overall response rate of 93%. Read More ›

Among patients with acute myeloid leukemia (AML), venetoclax added to a low-intensity backbone of cladribine plus low-dose Ara-C alternating with 5-azacitidine was an effective, well-tolerated regimen. Read More ›

Preliminary results from a phase 2 study of isatuximab in patients with amyloid light-chain (AL) amyloidosis who were previously treated showed encouraging efficacy and a good safety profile. Read More ›

Page 11 of 44

Conference Correspondent Coverage is Brought to You by the Publishers of:
CONQUER: the patient voice
Journal of Oncology Navigation & Survivorship
Oncology Practice Management
The Oncology Nurse–APN/PA
The Oncology Pharmacist
Value-Based Cancer Care

Learn more about our family of publications.

View Our Publications